ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
size factor · long-only model fund

Foundry Healthcare DolVol Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FDOHHYPOTHETICAL MODEL
Since ’99
−87%
Expense Ratio
0.45%
placeholder
Holdings
100
cap-weighted
Inception
Oct 2020
placeholder
Full Sharpe
-0.21
Ann. Return (LS)
-4.6%
Ann. Volatility
22.4%
Max Drawdown
-91.5%
Test Sharpe ’19–26
-0.65
Test FF5 α (ann.)
-10.7%
vs Fama-French 5
Test FF5 α t-stat
-1.28
not significant
Monthly turnover
31%
of the long leg, per rebalance
Cumulative return (LS)
-87%
over 331 months
This fund holds the long leg only
Long leg Sharpe
0.16
what this fund holds
Long leg ann. return
4.0%
buyable, long-only
Long-short Sharpe
-0.21
requires shorting
Bottom bucket ann. return
8.6%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

331 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

100 of 100 · 100.0% of book
TickerCompanySectorMarket capWeight
1INNV
INNOVAGE HOLDING CORPHealthcare$1.56B
5.18%
2ARDT
ARDENT HEALTH INCHealthcare$1.46B
4.83%
3SPTX
SEAPORT THERAPEUTICS INCHealthcare$1.12B
3.70%
4LMRI
LUMEXA IMAGING HOLDINGS INCHealthcare$1.07B
3.55%
5ODTX
ODYSSEY THERAPEUTICS INCHealthcare$846M
2.81%
6HSTM
HEALTHSTREAM INCHealthcare$832M
2.76%
7AURA
AURA BIOSCIENCES INCHealthcare$723M
2.40%
8BBOT
BRIDGEBIO ONCOLOGY THERAPEUTICS INCHealthcare$686M
2.28%
9SGP
SPYGLASS PHARMA INCHealthcare$661M
2.19%
10GYRE
GYRE THERAPEUTICS INCHealthcare$587M
1.95%
11FLGT
FULGENT GENETICS INCHealthcare$573M
1.90%
12NPCE
NEUROPACE INCHealthcare$548M
1.82%
13CTNM
CONTINEUM THERAPEUTICS INCHealthcare$532M
1.77%
14EIKN
EIKON THERAPEUTICS INCHealthcare$529M
1.76%
15CTEV
CLARITEV CORPHealthcare$518M
1.72%
16ARVN
ARVINAS INCHealthcare$517M
1.72%
17KIDS
ORTHOPEDIATRICS CORPHealthcare$494M
1.64%
18NRC
NRC HEALTHHealthcare$491M
1.63%
19OFIX
ORTHOFIX MEDICAL INCHealthcare$468M
1.55%
20VMD
VIEMED HEALTHCARE INCHealthcare$466M
1.55%
21PRTA
PROTHENA CORP PUBLIC LTD COHealthcare$453M
1.50%
22SI
SHOULDER INNOVATIONS INCHealthcare$448M
1.49%
23VREX
VAREX IMAGING CORPHealthcare$444M
1.47%
24BNTC
BENITEC BIOPHARMA INCHealthcare$439M
1.46%
25PBYI
PUMA BIOTECHNOLOGY INCHealthcare$434M
1.44%
26MOBI
MOBIA MEDICAL INCHealthcare$404M
1.34%
27ENTA
ENANTA PHARMACEUTICALS INCHealthcare$400M
1.33%
28DMAC
DIAMEDICA THERAPEUTICS INCHealthcare$393M
1.31%
29UPB
UPSTREAM BIO INCHealthcare$382M
1.27%
30EOLS
EVOLUS INCHealthcare$377M
1.25%
31FENC
FENNEC PHARMACEUTICALS INCHealthcare$365M
1.21%
32CV
CAPSOVISION INCHealthcare$335M
1.11%
33CARL
CARLSMED INCHealthcare$317M
1.05%
34LYEL
LYELL IMMUNOPHARMA INCHealthcare$311M
1.03%
35FHTX
FOGHORN THERAPEUTICS INCHealthcare$305M
1.01%
36TKNO
ALPHA TEKNOVA INCHealthcare$291M
0.96%
37MASS
908 DEVICES INCHealthcare$278M
0.92%
38SGHT
SIGHT SCIENCES INCHealthcare$274M
0.91%
39TTRX
TURN THERAPEUTICS INCHealthcare$272M
0.90%
40TRDA
ENTRADA THERAPEUTICS INCHealthcare$268M
0.89%
41CNXU
CONEXEU SCIENCES INCHealthcare$263M
0.87%
42ZSQR
Z SQUARED INCHealthcare$260M
0.86%
43SRZN
SURROZEN INCHealthcare$255M
0.85%
44RNAC
CARTESIAN THERAPEUTICS INCHealthcare$243M
0.81%
45ARTV
ARTIVA BIOTHERAPEUTICS INCHealthcare$241M
0.80%
46SMTI
SANARA MEDTECH INCHealthcare$229M
0.76%
47SPOK
SPOK HOLDINGS INCHealthcare$222M
0.74%
48UTMD
UTAH MEDICAL PRODUCTS INCHealthcare$222M
0.74%
49KPTI
KARYOPHARM THERAPEUTICS INCHealthcare$216M
0.72%
50SENS
SENSEONICS HOLDINGS INCHealthcare$214M
0.71%
51KROS
KEROS THERAPEUTICS INCHealthcare$211M
0.70%
52RNA
ATRIUM THERAPEUTICS INCHealthcare$208M
0.69%
53IMUX
IMMUNIC INCHealthcare$207M
0.69%
54BDSX
BIODESIX INCHealthcare$204M
0.68%
55FOCL
FOCAL INCHealthcare$204M
0.68%
56DTIL
PRECISION BIOSCIENCES INCHealthcare$203M
0.67%
57ANIK
ANIKA THERAPEUTICS INCHealthcare$203M
0.67%
58DERM
JOURNEY MEDICAL CORPHealthcare$197M
0.65%
59ACOG
ALPHA COGNITION INCHealthcare$185M
0.61%
60INFU
INFUSYSTEM HOLDINGS INCHealthcare$180M
0.60%
61INGN
INOGEN INCHealthcare$178M
0.59%
62KRRO
KORRO BIO INCHealthcare$177M
0.59%
63ARCT
ARCTURUS THERAPEUTICS HOLDINGS INCHealthcare$172M
0.57%
64CRBP
CORBUS PHARMACEUTICALS HOLDINGS INCHealthcare$167M
0.55%
65OWLT
OWLET INCHealthcare$162M
0.54%
66RCEL
AVITA MEDICAL INCHealthcare$157M
0.52%
67PMN
PROMIS NEUROSCIENCES INCHealthcare$136M
0.45%
68VTVT
VTV THERAPEUTICS INCHealthcare$130M
0.43%
69AARD
AARDVARK THERAPEUTICS INCHealthcare$128M
0.42%
70JYNT
JOINT CORPHealthcare$127M
0.42%
71CUE
CUE BIOPHARMA INCHealthcare$126M
0.42%
72OPRX
OPTIMIZERX CORPHealthcare$126M
0.42%
73SPRB
SPRUCE BIOSCIENCES INCHealthcare$120M
0.40%
74CPIX
CUMBERLAND PHARMACEUTICALS INCHealthcare$103M
0.34%
75ICCC
IMMUCELL CORPHealthcare$101M
0.33%
76VRCA
VERRICA PHARMACEUTICALS INCHealthcare$96M
0.32%
77PTHS
PELTHOS THERAPEUTICS INCHealthcare$94M
0.31%
78LIXT
LIXTE BIOTECHNOLOGY HOLDINGS INCHealthcare$91M
0.30%
79PARK
PARK DENTAL PARTNERS INCHealthcare$88M
0.29%
80RLYB
RALLYBIO CORPHealthcare$87M
0.29%
81CSBR
CHAMPIONS ONCOLOGY INCHealthcare$85M
0.28%
82NRXS
NEURAXIS INCHealthcare$84M
0.28%
83FRMM
FORUM MARKETS INCHealthcare$83M
0.27%
84PIII
P3 HEALTH PARTNERS INCHealthcare$78M
0.26%
85ACET
ADICET BIO INCHealthcare$76M
0.25%
86ATRA
ATARA BIOTHERAPEUTICS INCHealthcare$76M
0.25%
87CLNN
CLENE INCHealthcare$76M
0.25%
88NMAD
NOMAD POWER SOLUTIONS INCHealthcare$72M
0.24%
89SCLX
SCILEX HOLDING COHealthcare$72M
0.24%
90AGPU
AXE COMPUTE INCHealthcare$72M
0.24%
91LNSR
LENSAR INCHealthcare$70M
0.23%
92LONA
LEONABIO INCHealthcare$68M
0.23%
93IMA
IMAGENEBIO INCHealthcare$61M
0.20%
94EDSA
EDESA BIOTECH INCHealthcare$59M
0.19%
95SNWV
SANUWAVE HEALTH INCHealthcare$55M
0.18%
96INKT
MINK THERAPEUTICS INCHealthcare$53M
0.18%
97XLO
XILIO THERAPEUTICS INCHealthcare$53M
0.18%
98MCRB
SERES THERAPEUTICS INCHealthcare$52M
0.17%
99EXOZ
EXOZYMES INCHealthcare$51M
0.17%
100TIL
INSTIL BIO INCHealthcare$50M
0.17%

Full long-leg book as of July 2026 · cap-weighted · total market cap $30.13B. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

1 sectors
Healthcare
100.0%

Portfolio Style

Size × value map of the long-leg book

100 classified
Value
Blend
Growth
Large
Mid
Small
·
·
·
5%1
·
5%1
37%43
16%18
16%16

Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 6% toward Large, 37% toward Growth. +22% unclassified (21 missing size/value). Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt6% → Large
SmallLarge
Value ↔ growth tilt37% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 1998July 2026; the right-hand end is the same value as the box’s dot. 100 names now. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
4
Failed
2
Not tested
1
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

  • Days required to liquidate the largest position at 20% of one day's dollar volume.

    Required
    <= 7.0 days
    Actual
    22.1 days
    Margin
    -15.1 days
  • No more than 15% of net assets may be held in illiquid investments.

    Required
    <= 15.0%
    Actual
    22.6%
    Margin
    -7.6%
Reported separately — arithmetically implied

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

No verdict sits within 1.0pp of its limit.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 100 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
1.9 (95% CI 1.4-2.3)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
18.1%
99% / 20d
Reference
9.6%
FF5 market (mkt)

historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
1.88x
within
parametric
1.70x
within
cornish fisher
2.27x
over

The estimators agree, which is mild evidence the number isn’t an artefact of one method.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

published 1998
Entirely since publication
All 331 months of our record post-date the 1998 paper.
Sharpe -0.21-4.6% p.a.January 1999July 2026

There is no “before” to compare against — the predictor was already public when our data begins, so every month shown is out-of-sample relative to the original study.

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

26 windows
Positive windows
42%
11 of 26 3-year windows made money
Worst window
-1.26
Sharpe, January 2021 – December 2023
January 1999July 2026
Median Sharpe
-0.13
Dispersion
0.57
Best window
0.99

3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since January 1999
Trailing
PeriodLong legLong-short
1 yearcum.31.3%3.3%
3 yearsp.a.-0.7%-9.0%
5 yearsp.a.-22.6%-27.2%
10 yearsp.a.-7.3%-15.8%
Since inceptionp.a.0.5%-7.1%
Calendar years
YearLong legLong-short
20267 mo2.3%-2.2%
20254.8%-11.4%
2024-4.8%-8.1%
20232.3%0.2%
2022-66.2%-65.5%
2021-29.1%-43.2%
202024.5%8.2%
201921.0%0.4%
20182.4%-3.5%
201711.7%-7.6%
2016-8.8%-1.8%
2015-3.1%-9.4%
201426.9%0.8%
201370.9%20.7%
201226.5%8.4%
2011-15.0%-23.3%
201021.1%17.4%
20093.4%-14.6%
2008-42.7%-24.2%
20077.7%0.9%
200614.5%8.1%
20051.4%-7.2%
200417.7%15.4%
200365.5%39.2%
2002-31.9%-11.4%
200110.6%25.0%
2000-1.3%-28.9%
19990.1%-0.5%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FDOH
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.45% (placeholder)
Inception2020-10-22 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$30.13B

Methodology

The Foundry Healthcare DolVol Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a DolVol signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.